Experience the Quality With Free PANCE Exam Questions That Helps Candidates Pass

Guillain-Barré syndrome is an acute demyelinating polyneuropathy often after Campylobacter infection. Presents with ascending weakness, areflexia, and albuminocytologic dissociation in CSF (↑ protein, normal WBC). MG causes fatigable weakness. MS is CNS demyelination. ALS affects upper and lower motor neurons. PANCE neurology emphasizes recognizing GBS and urgent management with IVIG/plasmapheresis.

The mainstay of long-term asthma control is inhaled corticosteroids (ICS), which reduce airway inflammation and exacerbations. Oral steroids are for acute severe attacks. Leukotriene antagonists (e.g., montelukast) are adjuncts. Theophylline has limited role due to toxicity. PANCE requires recognition of stepwise asthma management guidelines.

IV drug use is strongly associated with Staphylococcus aureus infective endocarditis, most often involving the tricuspid valve. Rheumatic heart disease predisposes to Streptococcus viridans. Prosthetic valves are often infected by Staphylococcus epidermidis. Mitral valve prolapse predisposes to subacute endocarditis, not acute S. aureus. PANCE emphasizes pathogen–risk factor associations in endocarditis.

This patient has Cushing syndrome. The low ACTH indicates an ACTH-independent cause, most likely an adrenal adenoma secreting cortisol. A pituitary adenoma (Cushing disease) would have elevated ACTH. Ectopic ACTH (e.g., small cell lung cancer) also raises ACTH. Chronic exogenous steroids are the most common cause of Cushing features overall but usually suppress both cortisol and ACTH levels. This integrates endocrine pathophysiology, lab interpretation, and differential diagnosis—critical for PANCE objectives.

Primary hypothyroidism presents with high TSH and low free T4. Treatment is lifelong replacement with levothyroxine. Methimazole and radioactive iodine are for hyperthyroidism. Propranolol is used to control symptoms of hyperthyroidism, not hypothyroidism. Monitoring is based on TSH levels every 6–8 weeks after dose changes. Understanding endocrine lab interpretation and targeted therapy is fundamental for PANCE.